Introduction {#s1}
============

Tumors exhibit altered metabolism compared to non-transformed tissues ([@bib22]). For example, animal limbs transformed with oncogenic viruses exhibit increased glucose uptake and lactate secretion relative to unaffected limbs ([@bib19]). Some aspects of tumor metabolism, including higher rates of glucose fermentation to lactate, are cell-intrinsic features that are retained when cancer cells are isolated from tumors ([@bib57]). Indeed, numerous studies have delineated how cell-intrinsic factors such as oncogenic lesions or epigenetic state alter cellular metabolism, causing phenotypes such as increased glycolysis ([@bib74]).

However, beyond cell-intrinsic alterations, tumors have modified tissue architecture and an altered tissue microenvironment; these cell-extrinsic factors can also impact the metabolism of tumors ([@bib72]). For instance, the metabolic utilization of both glucose and the amino acid glutamine differs between cells growing in culture and murine tumor models ([@bib21]; [@bib71]; [@bib91]; [@bib100]). Further, the metabolic enzymes that cancer cells rely upon for proliferation in culture are different than those that the same cells utilize to support growth and survival in tumors ([@bib2]; [@bib81]; [@bib110]). Thus, cancer cell metabolism is influenced by microenvironmental cues.

Numerous microenvironmental factors affect cancer cell metabolism ([@bib3]; [@bib7]; [@bib72]; [@bib108]), including the presence of stromal cells ([@bib62]; [@bib69]), tumor acidity ([@bib18]; [@bib79]), extracellular matrix properties ([@bib23]; [@bib102]) and tumor nutrient levels ([@bib73]). In particular, environmental nutrient availability is an important regulator of cancer cell metabolism ([@bib12]; [@bib71]; [@bib90]; [@bib100]). Nutrient differences between standard cell culture and animal tumor models can drive substantial changes in cancer cell metabolism that alter the response of cancer cells to metabolically targeted drugs ([@bib12]; [@bib37]; [@bib71]; [@bib77]), such that drugs that inhibit proliferation of cancer cells in culture fail to exhibit efficacy in tumors derived from the same cells ([@bib8]; [@bib21]). Thus, determining the concentrations of nutrients in the tumor microenvironment is important to understand and therapeutically target cancer cell metabolism.

Tumors and tissues are supplied with nutrients through the vasculature, which filters a nutrient rich fluid from the circulation into the interstitial space of a tissue or tumor ([@bib107]). The interstitial fluid (IF) then perfuses through the tissue or tumor, exchanging nutrients and wastes with cells. IF is then drained from the tissue or tumor via capillaries and the lymphatic system. Thus, cells in tissues or tumors are not necessarily directly exposed to the nutrients in circulating plasma, but instead are exposed to IF nutrient levels. For healthy organs, IF nutrient levels may be similar to circulating nutrient levels, as these tissues are well vascularized, allowing rapid metabolic exchange with the plasma. Indeed, the IF glucose concentration in healthy skin is very similar to that of circulating plasma ([@bib61]). In contrast to the functional vessels found in normal tissues, tumors commonly have an abnormal vasculature with few vessels transporting blood ([@bib32]). This may lead to reduced nutrient delivery and waste exchange between tumor cells and the circulation. Thus, tumor interstitial fluid (TIF) is thought to be nutrient depleted compared to either normal tissues or the circulation, and have increased concentrations of metabolic waste products. Indeed glucose levels in the TIF of some tumors are lower than in the circulation, while lactate levels are higher ([@bib10]; [@bib38]; [@bib43]). However, despite the importance of nutrient availability in regulating tumor metabolism and drug sensitivity, TIF nutrients beyond glucose and lactate have not been comprehensively measured, and the factors that determine TIF composition have not been characterized.

We sought to systematically measure absolute nutrient concentrations in plasma and TIF. To do so, we have utilized a quantitative mass spectrometry-based approach using both external standards and stable isotope dilution of a library of carbon labeled metabolites to determine the concentration of \>118 nutrients in biological fluids. We applied this technique to measure nutrient levels in plasma and TIF isolated from autochthonous and transplantation models of murine lung (LUAD) and pancreatic adenocarcinomas (PDAC) driven by activation of Kras and deletion of p53. Interestingly, we found that anatomical location and tumor tissue of origin are both major determinants of TIF nutrient composition. Dietary changes are also reflected in TIF nutrient levels, while introduction of a *Keap1* mutation into LUAD cells had a smaller effect on the composition of the metabolic tumor microenvironment. Collectively, these experiments elucidate the microenvironmental constraints placed upon tumor metabolism by TIF nutrient levels and provide insight into the factors that dictate tumor nutrient availability.

Results {#s2}
=======

Isolation of TIF from murine PDAC tumors {#s2-1}
----------------------------------------

We first focused on isolating and analyzing TIF nutrient levels in pancreatic ductal adenocarcinoma (PDAC), as this tumor type is known to have inadequate vasculature leading to tumor hypoxia ([@bib56]) and nutrient deprivation ([@bib17]; [@bib55]; [@bib62]; [@bib92]; [@bib95]). End-stage tumors were isolated from the *LSL-Kras^G12D/+^; Trp53^flox/flox^; Pdx-1-Cre*, (KP-/-C) mouse model of PDAC ([@bib4]). This mouse model recapitulates many aspects of the human disease including dense stroma ([@bib4]) and alterations in systemic metabolism ([@bib20]; [@bib64]). We applied a previously described method to collect TIF; tumors were placed on a fine mesh and subjected to low speed centrifugation ([Figure 1A](#fig1){ref-type="fig"}) ([@bib40]). This method has previously been used to study glucose and lactate levels in tumor samples ([@bib43]; [@bib93]).

![Stable Isotope dilution can be utilized to analyze the composition of TIF.\
(**A**) Schematic of TIF isolation. (**B**) LDH activity assay measuring the amount of LDH present in whole tumors, plasma, and TIF from PDAC tumor bearing mice. LDH activity was calculated for the entire volume of TIF isolated from one tumor and plotted as a ratio to the amount of LDH present in the whole tumor lysate. For each TIF sample, an equal volume of plasma was analyzed and compared to the tumor lysate. n = 3 tumors, plasma, and TIF samples each. (**C**) Schematic summarizing the method used for TIF quantification. (**D**) LC/MS measurement of equal concentrations of 70 ^13^C chemical standards suspended in either water or mouse plasma. Data are plotted as the log~2~ fold change between the peak area of the metabolite in water versus in plasma. n = 19 plasma samples and n = 6 water samples.\
10.7554/eLife.44235.007Figure 1---source data 1.^13^C metabolite peak areas of metabolites suspended in plasma and water for matrix effect analysis in [Figure 1C](#fig1){ref-type="fig"}.](elife-44235-fig1){#fig1}

Critically, this centrifugation method does not cause lysis of cells when performed on human tumor samples, ensuring that the isolated fluid is interstitial and not intracellular fluid ([@bib40]). By measuring LDH activity (an intracellular enzyme and marker of intracellular fluid) in KP-/-C tumor, plasma, and TIF samples, we determined that the LDH activity in the entire TIF volume is \<1% of LDH activity found in the tumor ([Figure 1B](#fig1){ref-type="fig"}). Though levels of LDH activity in the PDAC TIF samples were \~20 fold higher than those found in plasma samples, similar or higher LDH activities were recovered in TIF of solid tumors isolated by orthogonal methods (\~60--80 fold higher LDH activity in TIF than plasma) ([@bib10]). These data further confirm that TIF isolation by centrifugation does not result in gross cell lysis and that intracellular fluid is not a major component of PDAC TIF.

The TIF isolation method employed requires tumor removal from the animal and centrifugation for 10 min. The time elapsed during this process could alter TIF composition. Faster TIF isolation was not possible, precluding direct assessment of how the time that elapses during TIF isolation impacts metabolites measured. However, to gain insight into whether tumor removal and centrifugation could potentially cause major alterations in tumor metabolism and thus TIF composition, we measured relative intratumoral levels of 112 metabolites in paired PDAC tumor pieces that were dissected from animals and then either frozen immediately or subjected to TIF isolation prior to freezing. Included in this analysis were levels of succinate, xanthine and hypoxanthine, metabolites shown previously to change in response to ischemia ([@bib16]). Principle component analysis did not lead to separate clustering of immediately frozen or TIF-isolated samples ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We found no increase in succinate and only modest increases in xanthine and hypoxanthine levels in tumors samples subjected to TIF isolation ([Figure 1---figure supplement 1B--D](#fig1s1){ref-type="fig"}), and the changes observed in xanthine and hypoxanthine were much less than those observed in ischemic tissues ([@bib16]). These data suggest that the TIF isolation method used does not cause substantial changes in intratumoral metabolite levels; however, development of faster TIF isolation methods will be required to rigorously evaluate the extent to which the metabolite composition of TIF is altered by the time needed to isolate this fluid.

We attempted to harvest IF from the pancreas, liver and brain of healthy non-tumor bearing animals using the same centrifugation protocol. We were not successful in isolating sufficient IF for analysis, perhaps due to the small size of murine organs and/or the lower interstitial fluid volume and pressure of healthy tissues compared to tumors ([@bib51]). Therefore, our analysis is limited to comparing TIF and plasma from tumor bearing animals.

The metabolite composition of PDAC TIF differs from plasma {#s2-2}
----------------------------------------------------------

In order to understand the metabolite composition of TIF and plasma samples, we utilized liquid chromatography/mass spectrometry (LC/MS) and both stable isotope dilution and external standard calibration to quantify metabolites ([Figure 1C](#fig1){ref-type="fig"} and Materials and methods for experimental and data analysis details). We assembled a library of 149 chemical standards of polar metabolites detected in previous studies of human plasma metabolite levels ([@bib12]; [@bib30]; [@bib59]; [@bib66]) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). We used these standards to quantify ^13^C labeled metabolites from yeast extracts derived from cultures where ^13^C is the only carbon source. Quantification of these ^13^C labeled metabolites allowed them to be used as internal standards for absolute quantification of metabolites by stable isotope dilution ([Figure 1C](#fig1){ref-type="fig"}). This enabled quantification of 70 metabolites, with the remaining 79 being quantified by external calibration using the library of chemical standards ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

Absolute LC/MS quantification of metabolites in biological samples such as plasma and TIF is complicated by matrix effects, which alter the ionization and detection of metabolites in different sample types ([@bib101]). Indeed, when the same amounts of ^13^C stable isotope labeled metabolites were added to water or mouse plasma, detected levels of these ^13^C standards varied widely depending on whether the metabolites were dissolved in water or plasma ([Figure 1D](#fig1){ref-type="fig"}). This result confirms the presence of significant matrix effects that confound the comparison of metabolite concentrations measured in different sample types and interfere with absolute quantification by external standard calibration. However, both ^12^C and ^13^C metabolites are subject to the same sample-dependent ion enhancement or suppression effects, so quantification by stable isotope dilution does not suffer from these potential systematic errors ([@bib101]). Therefore, we consider the concentrations assigned by external standard calibration to be semi-quantitative, in contrast to the quantitative measurements made by stable isotope dilution. By either isotope dilution or external calibration, we measured between 118--136 metabolites in individual experiments analyzing plasma and TIF with high levels of inter-day reproducibility (stable isotope dilution: Pearson r = 0.9536, p\<0.0001; external standard calibration: Pearson r = 0.9516, p\<0.0001) ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Low abundance metabolites that were not robustly and reproducibly detected were excluded from individual experiments. Together, this approach allowed us to obtain a combination of quantitative and semi-quantitative measurements of metabolite concentrations in both plasma and TIF.

To determine if the metabolic composition of TIF differs from that of plasma, we isolated TIF and plasma from PDAC tumor bearing mice. Methods of blood collection that require anesthesia can alter circulating metabolite levels ([@bib76]) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Therefore, to ensure that plasma samples would be directly comparable to TIF, plasma samples were isolated from mice via cardiac puncture upon euthanasia.

PDAC TIF and plasma samples were profiled using the described metabolomics techniques and grouped by either hierarchical clustering ([Figure 2A](#fig2){ref-type="fig"}) or principal component analysis ([Figure 2B](#fig2){ref-type="fig"}) of metabolite concentrations. By each method, the PDAC TIF samples clustered separately from the plasma samples, suggesting that the metabolic composition of PDAC TIF differs from that of plasma. Interestingly, there was substantial heterogeneity in plasma metabolite concentrations between animals. Plasma and TIF was not harvested from mice at a fixed time, and this heterogeneity in plasma metabolites might arise from differences in feed/fast cycle upon harvesting ([@bib99]) or circadian fluctuations in circulating metabolites ([@bib1]). PDAC TIF and plasma exhibit different matrix effects ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), which could contribute to the observed global differences in metabolite levels between TIF and plasma. Therefore, we also conducted a comparison of PDAC TIF and plasma metabolite levels using only metabolites quantified by stable isotope dilution. PDAC TIF is still substantially different from plasma when analysis is limited to only metabolites quantitated using isotopically labeled internal standards ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}), suggesting that the global metabolite composition of TIF differs from that of plasma.

![TIF metabolite levels are different than those in plasma.\
(**A**) Hierarchical clustering of PDAC TIF and mouse plasma samples based on LC/MS measurements of 136 metabolite concentrations. (**B**) Principal component analysis of PDAC TIF samples and mouse plasma samples based on LC/MS measurements of 136 metabolite concentrations. (**C**) Volcano plot depicting the log~2~ fold change in metabolite concentration between PDAC TIF and plasma. A fold change of 1.5 and a raw p-value of 0.01 assuming unequal variance were used to select significantly altered metabolites indicated in pink. LC/MS measurements of glucose (**D**), lactate (**E**), glutamine (**F**), arginine (**G**), tryptophan (**H**), alanine (**I**), cystine (**J**), and ornithine (**K**) in PDAC TIF and plasma samples. p-values were derived from unpaired, two-tailed Welch's t tests for all metabolites except glutamine (**F**) and tryptophan (**H**), which did not pass the Shapiro-Wilk test for normal distribution. These p-values were derived from a Wilcoxon-Mann-Whitney test. For all panels, n = 7 for PDAC TIF and n = 18 for plasma samples.\
10.7554/eLife.44235.018Figure 2---source data 1.Concentrations of 136 metabolites determined by both external standard calibration and stable isotope dilution in all PDAC TIF and plasma samples in [Figure 2](#fig2){ref-type="fig"}.](elife-44235-fig2){#fig2}

The composition of TIF is determined by the summed consumption and excretion rates of nutrients by all cells in the tumor microenvironment, and the exchange rate of those metabolites between the TIF and circulation or lymph; thus, TIF composition does not allow for extrapolation of the rates of consumption and excretion of nutrients from tumors. However, if the exchange rate of TIF and the whole-body circulation is slow or compromised, then nutrients that are highly consumed by cells within a tumor may be depleted in the TIF relative to the circulation, while metabolic by-products may accumulate. Therefore, we predicted that nutrients that are highly consumed by tumors and cancer cells in culture may be depleted in TIF, and metabolites excreted by tumors may accumulate in TIF. Consistent with the avid consumption of glucose observed in tumors and cancer cell lines, glucose was depleted in TIF compared to plasma ([Figure 2C--D](#fig2){ref-type="fig"}). Amino acids known to be produced by tumors such as glycine and glutamate ([@bib45]; [@bib53]) were enriched in TIF ([Figure 2C](#fig2){ref-type="fig"}). Interestingly, the amino acid glutamine, which is consumed rapidly by cultured cells ([@bib27]; [@bib45]; [@bib53]), was present at similar concentrations in TIF and plasma ([Figure 2C,E](#fig2){ref-type="fig"}). We also found that alanine, an amino acid reported to support PDAC cells ([@bib95]), was abundantly present in both TIF and plasma ([Figure 2F](#fig2){ref-type="fig"}). Further, metabolites important for immune cell function such as arginine, tryptophan and cystine ([@bib34]; [@bib68]; [@bib96]) were depleted in PDAC TIF compared to plasma ([Figure 2C,G--I](#fig2){ref-type="fig"}). Additionally, levels of ornithine in PDAC TIF increased relative to plasma, suggesting that local arginase activity ([@bib11]) may account for PDAC depletion of arginine ([Figure 2J](#fig2){ref-type="fig"}). Many metabolites were enriched in TIF ([Figure 2C](#fig2){ref-type="fig"}), suggesting that the PDAC tumor microenvironment is not depleted for all nutrients. Instead, PDAC TIF is composed of a complex mix of metabolites that are different from those present in circulation.

Tumor size does not dictate PDAC TIF composition {#s2-3}
------------------------------------------------

Having established that PDAC TIF composition is different from that of plasma, we next sought to understand the factors that influence TIF composition. We hypothesized that five factors could influence TIF composition: tumor size, anatomical location, tumor tissue of origin, diet, and tumor genetics. We used mouse models of PDAC and LUAD to systematically test the impact of these factors on TIF nutrient composition. First, we sought to test if the size of tumors influenced the composition of TIF. Since murine PDAC tumors cause morbidity at different times and tumor sizes, we were able to isolate TIF from end stage PDAC tumors of varying sizes (0.31 g -- 2.81 g). We tested if tumor size significantly altered TIF composition by comparing TIF metabolite concentrations between large (1.71--1.24 g) and small (0.78--1.22 g) PDAC tumors ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). We found that, at least within this size range of tumors, tumor size does not appear to dictate PDAC TIF metabolite levels.

Tumor location affects the composition of TIF {#s2-4}
---------------------------------------------

We hypothesized that PDAC tumors growing in the pancreas, with its diverse set of stromal cells and poor vascularization, might have different TIF composition than the same tumor cells growing in other organs or anatomical locations in the body. To test this hypothesis, we compared the metabolic composition of TIF from autochthonous KP-/-C PDAC tumors to that of tumors derived by subcutaneously injecting PDAC cells isolated from KP-/-C tumors into genetically identical C57BL/6J mice ([Figure 3A](#fig3){ref-type="fig"}). We did not observe any relationship between tumor type and the volume of TIF isolated (data not shown). Based on measurement of 123 quantitated metabolites that were detectable and quantifiable in this experiment, PDAC TIF was metabolically distinct from TIF derived from isogenic subcutaneous tumors both by principal component analysis ([Figure 3B](#fig3){ref-type="fig"}) and by hierarchical clustering ([Figure 3C](#fig3){ref-type="fig"}). Interestingly, concentrations of tryptophan, arginine and cystine, which are depleted in autochthonous PDAC TIF, were relatively higher in subcutaneous PDAC TIF ([Figure 3D--F](#fig3){ref-type="fig"}). This suggests that subcutaneous models of PDAC may not mimic the metabolic microenvironment of PDAC tumors. Furthermore, while potentially confounded by comparing transplant and autochthonous PDAC models, these results suggest that the metabolic composition of TIF is not only determined by tumor-intrinsic factors, but potentially also by the anatomical location in which the tumor is growing.

![Tumor location dictates metabolic TIF composition.\
(**A**) Diagram of experimental models used to test the effect of tumor location on TIF metabolite levels. Principal component analysis (**B**) and hierarchical clustering (**C**) of PDAC TIF and PDAC subcutaneous allograft TIF samples based on LC/MS measurements of 123 metabolite concentrations. LC/MS measurements of tryptophan (**D**), arginine (**E**), and cystine (**F**) in PDAC TIF and PDAC subcutaneous allograft TIF. p-values were derived from unpaired, two-tailed Welch's t tests. For all panels, n = 7 for PDAC TIF samples and n = 5 for PDAC subcutaneous allografts.\
10.7554/eLife.44235.025Figure 3---source data 1.Concentrations of 123 metabolites determined by both external standard calibration and stable isotope dilution in all autochthonous and subcutaneous PDAC TIF samples in [Figure 3](#fig3){ref-type="fig"}.](elife-44235-fig3){#fig3}

Dietary changes alter TIF composition {#s2-5}
-------------------------------------

Though TIF metabolite levels do not match those found in plasma, factors that influence circulating nutrient levels may be reflected in TIF. One important determinant of plasma metabolite levels is diet; thus, we examined whether dietary changes would alter TIF metabolite levels. For this analysis, we isolated TIF from isogenic PDAC subcutaneous allografts in mice fed either standard mouse chow derived from plant and animal products or a defined diet that replaces whole protein with purified amino acids ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). This allows us to compare genetically identical tumors growing in the same anatomical location, where only diet is altered. These diets contain many differences in nutrient levels, providing a test case to determine whether significant dietary alterations affect TIF metabolite levels. Based on measurement of 123 metabolites that were detectable and quantifiable in this experiment, TIF from mice fed standard chow differed from TIF from mice fed a defined diet based on principal component analysis ([Figure 4B](#fig4){ref-type="fig"}) and hierarchical clustering ([Figure 4C](#fig4){ref-type="fig"}).

![Dietary changes alter TIF composition.\
(**A**) Schematic of experimental models used to test the effect of diet on TIF metabolite levels. Principal component analysis (**B**) and hierarchical clustering (**C**) of subcutaneous PDAC allograft TIF samples from mice fed standard mouse chow versus mice fed a defined diet based on LC/MS measurements of 123 metabolite concentrations. (**D**) Ratios of LC/MS measurements of 123 metabolites in TIF versus matched plasma from the same mouse fed standard mouse chow plotted versus the same ratios in mice fed a defined diet. For all panels, n = 5 for TIF from mice fed standard mouse chow and n = 3 for TIF from mice fed a defined diet.\
10.7554/eLife.44235.029Figure 4---source data 1.Concentrations of 123 metabolites determined by both external standard calibration and stable isotope dilution in all plasma and subcutaneous PDAC TIF samples in [Figure 4](#fig4){ref-type="fig"}.](elife-44235-fig4){#fig4}

We next wanted to determine if the changes in TIF composition between diets were primarily due to altered nutrient availability to TIF from circulation, or if other physiological effects of altered diet were affecting TIF. If dietary perturbations primarily affect TIF by simply altering plasma nutrient levels, then the concentration of a metabolite in TIF should correlate with its concentration in plasma to the same degree in both dietary conditions. Thus, if a dietary change increases the plasma level of a metabolite, then the TIF concentration of that metabolite should also increase. Indeed, there is a strong correlation (Pearson r = 0.8927, p\<0.0001) between TIF to plasma ratio of metabolite concentrations between mice on different diets ([Figure 4D](#fig4){ref-type="fig"}). Furthermore, linear regression of TIF to plasma ratios in mice fed different diets nearly yields an identity function (slope = 0.9511, R^2^ = 0.7969) ([Figure 4D](#fig4){ref-type="fig"}). Thus, while individual TIF metabolite levels are scaled by some factor relative to plasma levels, dietary perturbation does not broadly affect this scaling factor. Thus, in addition to local microenvironmental factors, systemic metabolic changes can affect the composition of TIF by altering circulating nutrient levels.

Tumor tissue of origin affects TIF makeup {#s2-6}
-----------------------------------------

Tumor location and circulating metabolite levels are cell-extrinsic factors that influence the TIF composition. However, there exist many cell-intrinsic factors that alter cancer cell metabolism. For instance, the metabolic properties of cancer cells depend upon the tissue from which they originated ([@bib46]; [@bib65]; [@bib112]). To examine whether tissue of origin influences the metabolic makeup of the tumor microenvironment, cancer cells derived from lung ([@bib50]; [@bib49]) and PDAC ([@bib4]) tumors both driven by activation of *Kras* and loss of *Trp53* were injected subcutaneously into C57BL/6J mice, such that tumors were established in the same location and with the same oncogenic driver mutations, but different tissues of origin ([Figure 5A](#fig5){ref-type="fig"}). Based on measurement of 104 metabolites that were detectable and quantifiable in this experiment, TIF from subcutaneous tumors derived from LUAD clustered separately from PDAC subcutaneous allograft TIF by principal component analysis ([Figure 5B](#fig5){ref-type="fig"}) and hierarchical clustering ([Figure 5C](#fig5){ref-type="fig"}). Similar results were obtained when the analysis was limited to only metabolites quantitated by stable isotope dilution ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). LUAD and PDAC tumors are known to have different branched-chain amino acid metabolism ([@bib65]), and levels of branched-chain amino acids and their catabolites were different between LUAD and PDAC tumors ([Figure 5D](#fig5){ref-type="fig"}). Additionally, a number of metabolites involved in thiol metabolism are altered between LUAD and PDAC tumors ([Figure 5D](#fig5){ref-type="fig"}) ([@bib33]; [@bib48]), suggesting potential differences in sulfur metabolism between these tumors. Collectively, these data suggest that tissue of origin is a determinant of the metabolic composition of TIF.

![Tumor tissue of origin influences TIF composition independent of tumor location.\
(**A**) Diagram of experimental models used to test the effect of tumor tissue of origin on TIF metabolite levels. Principal component analysis (**B**) and hierarchical clustering (**C**) of PDAC subcutaneous allograft TIF and LUAD subcutaneous allograft TIF samples based on LC/MS measurements of 104 metabolite concentrations. (**D**) Volcano plot depicting the log~2~ fold change in metabolite concentration between PDAC and LUAD TIF for metabolites measured using stable isotope dilution. A fold change of 1.5 and raw p-value of 0.01 assuming unequal variance were used to select significantly altered metabolites indicated in pink. For all panels, n = 5 for PDAC subcutaneous allograft TIF samples and n = 10 for LUAD subcutaneous allograft TIF samples.\
10.7554/eLife.44235.034Figure 5---source data 1.Concentrations of 104 metabolites determined by both external standard calibration and stable isotope dilution in all subcutaneous PDAC and LUAD TIF samples in [Figure 5](#fig5){ref-type="fig"}.](elife-44235-fig5){#fig5}

Genetic loss of the tumor suppressor Keap1 does not have a large effect on TIF composition {#s2-7}
------------------------------------------------------------------------------------------

Genetic alterations can profoundly alter cancer metabolism ([@bib74]). As a test case for whether tumor genetics can influence the metabolism of TIF, we focused on the tumor suppressor *Keap1. Keap1* loss is a common occurrence in lung cancer that alters expression of oxidative stress response genes and nutrient transporters, which causes cells to secrete high levels of glutamate and renders tumors highly dependent on glutamine catabolism for growth ([@bib85]; [@bib88]). Thus, *Keap1* null tumors may possess remodeled metabolism that would be reflected in TIF composition. To test this possibility, we injected previously described LUAD cells with wild-type *Keap1* (sgControl) or *Keap1* loss (sg*Keap1*) ([@bib85]) subcutaneously into the flanks of C57BL/6J mice ([Figure 6A](#fig6){ref-type="fig"}), and TIF was isolated from these tumors. Based on measurement of 131 metabolites that were detectable and quantifiable in this experiment, TIF samples did not cluster separately based on *Keap1* status by principal component analysis ([Figure 6B](#fig6){ref-type="fig"}), although they could be separated by hierarchical clustering ([Figure 6C](#fig6){ref-type="fig"}). Surprisingly, anticipated changes in TIF composition based on alterations to cancer cell metabolism by *Keap1* loss, such as decreased glutamine, glucose and cystine, and increased glutamate and lactate ([@bib85]) were not observed between TIF samples of *Keap1* wild-type and *Keap1* null tumors ([Figure 6D--H](#fig6){ref-type="fig"}). Together, these results suggest that genetic *Keap1* status has less of an effect on metabolic TIF content in subcutaneous lung cancer allografts, and that not all cancer cell-intrinsic perturbations of metabolism cause detectable changes to the tumor nutrient milieu.

![Genetic *Keap1* status is not a major determinant of TIF composition in subcutaneous LUAD allograft tumors.\
(**A**) Schematic of experimental models used to test the effect of genetic loss of *Keap1* on TIF metabolite levels. Principal component analysis (**B**) and hierarchical clustering (**C**) of *Keap1* wild-type (sgControl) and *Keap1* null (sgKeap1) subcutaneous LUAD allograft TIF samples based on LC/MS measurements of 131 metabolite concentrations. LC/MS measurements of glucose (**D**), lactate (**E**), glutamine (**F**), glutamate (**G**), and cystine (**H**) in *Keap1* wild-type (sgControl) and *Keap1* null (sgKeap1) subcutaneous lung allograft TIF samples. p-values were derived from unpaired, two-tailed Welch's t tests. For all panels, n = 10 for sgControl subcutaneous lung allograft TIF samples and n = 8 for sgKeap1 subcutaneous LUAD allograft TIF samples.\
10.7554/eLife.44235.039Figure 6---source data 1.Concentrations of 131 metabolites determined by both external standard calibration and stable isotope dilution in all sgControl and sg*Keap1* LUAD TIF samples in [Figure 6](#fig6){ref-type="fig"}.](elife-44235-fig6){#fig6}

Discussion {#s3}
==========

Pancreatic and lung tumor cells are exposed to nutrient levels that differ from those found in plasma {#s3-1}
-----------------------------------------------------------------------------------------------------

Intravital imaging of tumors in patients ([@bib31]) and murine cancer models ([@bib32]) has revealed that solid tumors generally have abnormal and dysfunctional vasculature and lymphatic vessels. For example, only \~30% of PDAC blood vessels appear functional ([@bib75]). This is thought to limit nutrient delivery from the circulation to tumors both by reducing blood flow and by inhibiting transcapillary filtration due to increased interstitial pressure ([@bib98]). PDAC tumors in particular have striking defects in vasculature with numerous collapsed vessels triggered by increased interstitial pressure ([@bib26]; [@bib82]) or solid stress ([@bib14]). In contrast to normal tissues, which, while not in perfect metabolic equilibrium with the circulation ([@bib13]) are reported to have nutrient levels close to what is in the circulation ([@bib61]), it is unlikely that the interstitial environment of tumors is in rapid exchange with the circulation. Coupled with the high metabolic rate of cancer cells, this has led to speculation that tumors will be both nutrient deprived and accumulate metabolic wastes. We find that TIF metabolite levels in the murine cancer models assessed are different from the nutrient levels in plasma. Contrary to many assumptions, not all nutrients are depleted in TIF, with levels of some being higher than what is found in circulation. Thus, our measurements of plasma and TIF nutrient composition are consistent with a model where tumors with abnormal vasculature exist largely as a separate compartment from the bulk circulation, and can have different steady state metabolic microenvironments. This underscores the importance of understanding TIF composition for studies of tumor metabolism.

Interestingly, a number of existing and experimental therapies alter the vasculature and interstitial transport properties of tumors to increase tumor perfusion. For example, anti-VEGF therapies are thought to normalize tumor vasculature leading to decreased interstitial pressure and increased perfusion ([@bib52]), and a number of approaches have been developed to limit the stromal compression of tumor blood vessels that increases tumor pressure and decreases tumor perfusion ([@bib75]; [@bib80]; [@bib82]). Future studies to manipulate tumor perfusion will determine the extent to which tumor nutrient availability is influenced by stromal desmoplasia and altered tumor vasculature.

While we have considered the tumor as a single compartment and analyzed bulk TIF from the entire tumor, it is possible that the tumor contains a population of sub-compartments with different perfusion rates ([@bib41]) and heterogeneous TIF compositions ([@bib105]). Measurements of intratumor metabolites in subsections of tumors suggests that some tumor regions experience different nutrient levels than others ([@bib78]). Thus, while the overall tumor metabolic microenvironment differs from the circulation, an important future challenge will be to understand how compartmentalized nutrient delivery contributes to metabolic heterogeneity observed in solid tumors ([@bib41]).

Though TIF appears to constitute a separate compartment from plasma, tumor nutrients are ultimately delivered from the circulation. Thus, perturbations to systemic nutrient levels by altering diet affect TIF composition. This relationship between plasma and TIF nutrient levels across different diets suggests that TIF levels of metabolites are derived from plasma metabolite concentrations, and changes in plasma metabolite levels lead to scaled changes in TIF metabolite levels. This argues that a major mechanism by which diet influences tumor nutrient availability is by altering nutrients available in the circulation.

Tumor properties that influence the metabolic microenvironment {#s3-2}
--------------------------------------------------------------

Beyond dietary factors, we considered four variables that could influence tumor nutrient availability: tumor size, tissue of origin, tumor anatomical location and tumor genetic make-up. Though we observed that tumor size did not strongly affect the composition of TIF in PDAC tumors, we collected TIF from a relatively small range of sizes of end stage PDAC tumors. Future work to examine the TIF composition of tumors at various sizes and stages of development may reveal effects of tumor size on TIF nutrient levels.

The finding that PDAC and LUAD tumors have different TIF composition suggests that tissue of origin is a factor that can influence the metabolic microenvironment; however, the mechanism(s) driving this difference remain unclear. Whether cancer cell-intrinsic metabolic differences endowed by the epigenetic memory of the tissue of origin ([@bib46]; [@bib65]) or other cell-extrinsic differences between PDAC and LUAD, such as differences in non-cancer cells present in the tumor, drive the difference in TIF composition is another important question for future study.

Tumors in different anatomical locations will also contain different stromal cells and different vascularization that could alter the metabolic microenvironment. Comparison of autochthonous and subcutaneous PDAC tumors driven by the same oncogenic driver mutations revealed significant differences in TIF nutrient levels. This suggests that subcutaneous models of PDAC may not fully recapitulate the metabolic microenvironment of this disease, and is in line with observations that subcutaneous models of PDAC fail to recapitulate many aspects of PDAC tumors including marked stromal infiltration and extracellular matrix deposition ([@bib47]). These observations, along with recent findings that subcutaneous PDAC models do not recapitulate whole body metabolic perturbations observed in autochthonous PDAC models and patients ([@bib20]), suggest subcutaneous models do not recapitulate all metabolic aspects of the disease.

As we compared transplant to autochthonous PDAC models, we cannot distinguish between differences in TIF composition driven by anatomical location versus differences caused by unique characteristics of transplant and genetically engineered PDAC models. Nevertheless, it is intriguing that autochthonous PDAC tumors have lower levels of arginine, tryptophan and cystine compared to subcutaneous tumors. Stromal myeloid derived cells have been implicated in depleting each of these nutrients from the tumor microenvironment ([@bib58]), and murine PDAC tumors are known to contain a large number of myeloid lineage cells ([@bib5]; [@bib35]; [@bib97]; [@bib115]). Additionally, subcutaneous PDAC tumors are known to have fewer stromal cells ([@bib47]; [@bib95]). Thus, it is tempting to speculate that differences in TIF composition between autochthonous and subcutaneous PDAC tumors, including differences in arginine, tryptophan and cystine levels, could be driven by differences in stromal cell populations between anatomical sites. Understanding how anatomical location alters the metabolic microenvironment is critical to determine how local metabolic constraints shape the metabolism of tumors growing in different locations, such as primary and metastatic tumors ([@bib89]).

Lastly, we hypothesized that tumor genetics would also alter TIF composition, and studied the effect of *Keap1* loss because *Keap1* null cancer cells have dramatic alterations in cell-intrinsic metabolism ([@bib6]; [@bib25]; [@bib24]; [@bib67]; [@bib85]; [@bib88]). Surprisingly, we found no substantial differences in TIF composition between tumors formed from otherwise isogenic LUAD cell lines that differed only in *Keap1* loss. These data argue that factors beyond cancer cell-intrinsic metabolism can be dominant in setting nutrient levels in the microenvironment, although future studies are required to determine how other oncogenic alterations alter TIF composition.

Implications of TIF nutrient levels for cellular metabolism and function in the tumor {#s3-3}
-------------------------------------------------------------------------------------

It is tempting to interpret depletion or accumulation of metabolites as simply being due to rapid cancer cell consumption or release of metabolites without appropriate replenishment or removal from the circulation, allowing cancer cell-intrinsic changes in metabolism to be read out as differences in TIF nutrient levels. However, wild type and *Keap1* null cancer cells have significant changes in metabolism ([@bib6]; [@bib25]; [@bib24]; [@bib67]; [@bib85]; [@bib88]), yet tumors derived from cells of these genotypes do not show significant alterations in levels of nutrients whose metabolism is known to be altered by *Keap1* loss. Thus, differences in metabolite concentrations between TIF and plasma cannot be used to extrapolate consumption and release of metabolites by tumors. Instead, future experiments measuring differences in arterial and venous metabolite levels could shed light into quantitative tumor nutrient consumption and release ([@bib39]; [@bib54]; [@bib87]).

Nutrient levels in the tumor microenvironment can have profound impacts on the metabolism, growth and drug sensitivity of tumor resident cancer cells ([@bib72]). Our study provides insight into tumor nutrient levels in vivo and suggests specific implications for tumor resident cell metabolism. First, we find PDAC tumor interstitial fluid is depleted of some nutrients relative to plasma. Interestingly, these depleted nutrients are not necessarily metabolites predicted to be depleted by cell culture studies. For example, PDAC cells consume large amounts of glucose and glutamine in culture ([@bib94]; [@bib111]), and it has been assumed that these nutrients are depleted in the microenvironment ([@bib17]; [@bib55]; [@bib62]; [@bib92]; [@bib95]). Branched chain amino acids are also proposed to be limiting for proliferation of PDAC cells in tumors, requiring cancer cells to acquire those nutrients from alternative sources such as stromal cells or extracellular protein ([@bib36]; [@bib77]). We find that neither glutamine nor branched-chain amino acids are substantially depleted in PDAC tumors regardless of anatomical site. Further, while glucose is depleted in PDAC TIF relative to circulatory levels, it is still present at millimolar concentration, and glucose deprivation in TIF is not a universal feature of tumors ([@bib93]). Thus, nutrients inferred from cell culture studies to be depleted and limiting in the tumor microenvironment may not be always be key microenvironmental drivers altering PDAC metabolism.

We find that the nutrient most strongly depleted from PDAC TIF is arginine. Arginine supports many aspects of cell physiology ([@bib70]), raising the question of how PDAC cells adapt to survive and proliferate when levels of this amino acid are so low. Many cell types can synthesize arginine using urea cycle enzymes ([@bib109]), but these metabolic enzymes are silenced by many tumors to enhance nucleotide production ([@bib83]). However, PDAC tumors do not exhibit urea cycle enzyme silencing ([@bib60]; [@bib103]) and are reported to have a functional urea cycle ([@bib113]). Perhaps, PDAC cells retain this metabolic pathway to adapt to a tumor microenvironment with limited arginine availability. Additionally, PDAC cells utilize macropinocytosis of environmental protein ([@bib17]; [@bib55]), and this route of nutrient acquisition may allow PDAC cells to acquire sufficient arginine to support survival and growth.

TIF composition can alter the function of non-cancer cells, such as immune cells, in the tumor microenvironment ([@bib9]). For example, in many tumor types, T lymphocytes can infiltrate and inhibit the progression of tumors, especially when this process is primed with checkpoint blockade treatment ([@bib84]). In contrast, PDAC tumors are highly immunosuppressive ([@bib63]) and immunotherapy shows limited efficacy in this disease ([@bib42]). Nutrient deprivation in PDAC TIF could contribute to PDAC immunosuppression. Both arginine and tryptophan, which are depleted in the autochthonous PDAC environment, are required for T cell function ([@bib34]; [@bib68]). Intriguingly, depletion of myeloid cells capable of degrading arginine and tryptophan from PDAC tumors resulted in increased T cell infiltration, proliferation, and activation in PDAC tumors ([@bib5]; [@bib97]; [@bib114]). Future studies determining how T cell metabolism and function is impacted by tumor nutrient levels could yield insight into how tumors suppress immune rejection ([@bib28]).

Cellular metabolism can respond and adapt to environmental nutrient levels. Indeed, growing cancer cells in media with different nutrient compositions alters their metabolic requirements and response to drugs ([@bib12]; [@bib71]; [@bib77]; [@bib90]). That metabolism is responsive to environment may underpin the limited ability of ex vivo culture models using non-physiological nutrient levels to identify tumor-essential metabolic genes ([@bib44]; [@bib73]; [@bib86]). However, given the dearth of information on physiological nutrient levels in solid tumors, it has not been possible to determine the metabolic phenotypes and liabilities of cancer cells in tumor nutrient conditions. By characterizing the polar small molecule nutrients in PDAC and LUAD tumors, media that better approximates the nutrients available to cancer cells in tumors can be formulated. Examining non-polar and lipid metabolites in the microenvironment will further improve these efforts and lead to cancer models that may better allow us to identify metabolic liabilities of cancer cells that ultimately translate into more effective therapies.

Materials and methods {#s4}
=====================

Animal studies {#s4-1}
--------------

All experiments performed in this study were approved by the MIT Committee on Animal Care (IACUC). All mice in this study were fully backcrossed to the C57BL/6J background. Animals were housed on a 12 hr light and 12 hr dark cycle, with ad libitum access to food and water.

For studies using *Kras^G12D^ Trp53^fl/fl^ Pdx-1-cre* (KP-/-C) mice ([@bib4]), male and female animals of this genotype were allowed for form end-stage tumors, which occurred approximately 8--10 weeks after birth ([@bib20]). Animals were then euthanized and tumors harvested for TIF isolation as described below. Tumors weighed between 0.31 g -- 2.81 g upon harvesting.

For subcutaneous xenograft studies, 12 week old C57BL/6J animals purchased from Jackson Laboratories (IMSR Cat\# JAX:000664, RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)) were injected with 100,000 murine PDAC or LUAD cancer cells (suspended in a volume of 100 μL of Matrigel (Corning, 354234) brought to 10 mg/ml with RPMI-1640 (Corning, 50--020-PC) into the subcutaneous space on the flank of the mice. Cell lines used for subcutaneous engraftment in this study are described below. Tumors were then allowed to grow until they reached \~1 cm^3^ in volume, which took \~4 weeks after engraftment. Upon the tumor reaching \~1 cm^3^, animals were euthanized and tumors harvested for TIF isolation as described below.

For dietary studies, C57BL/6J mice were engrafted with murine PDAC cells as described above. On the day of injection, the animals were separated into two cohorts. One group was fed standard mouse chow and the other group was fed a defined amino acid diet (see [Supplementary file 2](#supp2){ref-type="supplementary-material"} for composition of diets). Both groups were fed each diet ad libitum throughout the duration of the experiment. Upon the tumor reaching 1 cm^3^, animals were euthanized and tumors harvested for TIF isolation as described below.

Cell lines and culture {#s4-2}
----------------------

The murine PDAC cancer cell line (AL1376) used for making subcutaneous grafts was generated as previously described ([@bib64]) from PDAC tumors from a KP-/-C animal in the C57BL/6J background. The C57BL/6J LUAD cancer cell lines with and without loss of *Keap1* used in tumor grafts in this study were generated previously ([@bib85]) from the *Kras^G12D^ Trp53^fl/fl^ Adenoviral-cre* model of LUAD ([@bib50]; [@bib49]). All cell lines were regularly tested for mycoplasma contamination using the Mycoprobe mycoplasma detection kit (R and D Systems). All cells were cultured in a Heracell (Thermofisher) humidified incubators at 37°C and 5% CO~2~. Cell lines were routinely maintained in RPMI-1640 (Corning, 50--020-PC) supplemented with 10% heat inactivated fetal bovine serum (Seradigm, Lot 120B14).

Isolation of tumor interstitial fluid (TIF) {#s4-3}
-------------------------------------------

TIF was isolated from tumors using a previously described centrifugal method ([@bib29]; [@bib40]; [@bib43]; [@bib106]). Briefly, tumor bearing animals were euthanized by cervical dislocation and tumors were rapidly dissected from the animals. Dissections took \<1 min. to complete. Blood was collected from the same animal via cardiac puncture, and was immediately placed in EDTA-tubes (Sarstedt, North Rhine-Westphalia, Germany) and centrifuged at 845 x g for 10 min at 4°C to separate plasma. Plasma was frozen in liquid nitrogen and stored at −80°C until further analysis. Tumors were then weighed and briefly rinsed in room temperature saline (150 mM NaCl) and blotted on filter paper (VWR, Radnor, PA, 28298--020). The entire process of preparing the tumor prior to isolation of TIF took \~2 min. The tumors were then put onto 20 µm nylon filters (Spectrum Labs, Waltham, MA, 148134) affixed atop 50 mL conical tubes, and centrifuged for 10 min. at 4°C at 106 x g. TIF was then collected from the conical tube, frozen in liquid nitrogen and stored at −80°C until further analysis. 5--180 µL of TIF was able to be isolated from \~75% (13/17 tumors) of isolated KP-/-C PDAC tumors. The remaining 25% of tumors did not yield any fluid. The amount of fluid collected per tumor weight is consistent with previous reports of TIF isolation from human tumor samples ([@bib40]).

Quantification of lactate dehydrogenase activity in TIF, plasma and tumors {#s4-4}
--------------------------------------------------------------------------

To quantitate the amount of LDH activity present in TIF, plasma, and tumors, we utilized the inherent absorbance of NADH at 340 nm to monitor the generation of lactate from pyruvate and NADH. To an assay buffer composed of 50 mM Tris base (Sigma Aldrich, 93362), 100 mM dithiothreitol (Sigma Aldrich, 646563), 180 μM NADH (Sigma Aldrich, N8129), and 500 μM pyruvate (Sigma Aldrich, P5280), we added 20 μL of sample, then monitored the disappearance over time of absorbance of light at 340 nM due to the consumption of NADH. A standard curve of LDH (Sigma-Aldrich, 10127230001, E.C. 1.1.1.27) was generated with points of 0, 0.005838, 0.007783, 0.011675, 0.02335, and 0.0467 units of LDH activity by diluting LDH in Tris buffered saline composed of 50 mM Tris HCl (VWR, 4103) and 150 mM NaCl (Sigma Aldrich, 746398) pH adjusted to 7.5. Whole tumor samples were prepared by homogenization using a mortar and pestle submerged in liquid nitrogen, and the resulting powder was resuspended at 10 mg/mL in Tris buffered saline. Plasma samples were added undiluted, and TIF samples were diluted 1:10 in Tris buffered saline. Based on the slope of the LDH standard curve, the amount of LDH activity in each sample was calculated and corrected for dilution.

Quantification of metabolite levels in TIF and plasma {#s4-5}
-----------------------------------------------------

In order to quantitate metabolites in TIF and plasma samples, we first constructed a library of 149 chemical standards of plasma polar metabolites (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for suppliers for each chemical standard). These compounds were selected to encompass a number of metabolic processes and have previously been included in efforts to profile plasma polar metabolites by LC/MS ([@bib12]; [@bib30]; [@bib59]; [@bib66]). We pooled these metabolites into seven separate chemical standard pools ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). To do this, each metabolite in a given pool was weighed and then mixed (6 cycles of 1 min. mixing at 25 Hz followed by 3 min. resting) using a Mixer Mill MM301 (Retsch, Düsseldorf, Germany), and mixed metabolite powder stocks were stored at −20°C prior to resuspension and analysis. Stock solutions of the mixed standards pools containing \~5 mM,\~1 mM,\~300 µM,\~100 µM,\~30 µM,\~10 µM,\~3 µM and \~1 µM of each metabolite were made in HPLC grade water and were stored at −80°C (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for the concentration of each metabolite in the external standard pools). We refer to these stock solutions as 'external standard pools' throughout. External standard pools were used to confirm the retention time and *m/z* for each analyte and provide standards to quantitate concentrations of stable isotope labeled internal standards used in downstream analysis, as well as to quantitate metabolite concentrations in TIF and plasma samples directly where internal standards were not available (see below for details).

We had three classes of samples: plasma, TIF and the external standard pool dilutions (prepared in water). We extracted polar metabolites ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) from each sample type using the same extraction mix and protocol: 5 µL of sample (plasma, TIF or external standard pool dilution) was mixed with 45 uL of acetonitrile:methanol:formic acid (75:25:0.1) extraction mix including the following isotopically labeled internal standards: ^13^C labeled yeast extract (Cambridge Isotope Laboratory, Andover, MA, ISO1), ^13^C~3~ lactate (Sigma Aldrich, Darmstadt, Germany, 485926), ^13^C~3~ glycerol (Cambridge Isotope Laboratory, Andover, MA, CLM-1510), ^13^C~6~ ^15^N~2~ cystine (Cambridge Isotope Laboratory, Andover, MA, CNLM-4244), ^2^H~9~ choline (Cambridge Isotope Laboratory, Andover, MA, DLM-549), ^13^C~4~ 3-hydroxybutyrate (Cambridge Isotope Laboratory, Andover, MA, CLM-3853), ^13^C~6~ glucose (Cambridge Isotope Laboratory, Andover, MA, CLM-1396), ^13^C~2~ ^15^N taurine (Cambridge Isotope Laboratory, Andover, MA, CNLM-10253), ^2^H~3~ creatinine (Cambridge Isotope Laboratory, Andover, MA, DLM-3653), 8-^13^C adenine (Cambridge Isotope Laboratory, Andover, MA, CLM-1654), ^13^C~5~ hypoxanthine (Cambridge Isotope Laboratory, Andover, MA, CLM-8042), 8-^13^C guanine (Cambridge Isotope Laboratory, Andover, MA, CLM-1019), ^13^C~3~ serine (Cambridge Isotope Laboratory, Andover, MA, CLM-1574) and ^13^C~2~ glycine (Cambridge Isotope Laboratory, Andover, MA, CLM-1017). All solvents used in the extraction mix were HPLC grade. Samples were then vortexed for 10 min. at 4°C and insoluble material was sedimented by centrifugation at 15 kg for 10 min. at 4°C. 20 µL of the soluble polar metabolite extract was taken for LC/MS analysis.

LC/MS analysis was performed on the sample extracts using a QExactive orbitrap mass spectrometer using an Ion Max source and heated electrospray ionization (HESI) probe coupled to a Dionex Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA). External mass calibration was performed every 7 days, and internal mass calibration (lock masses) was not used. 2 μL of each sample was injected onto a ZIC-pHILIC 2.1 × 150 mm analytical column equipped with a 2.1 × 20 mm guard column (both 5 μm particle size, EMD Millipore). The autosampler and column oven were held at 4°C and 25°C, respectively. Buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile. The chromatographic gradient was run at a flow rate of 0.150 mL/min as follows: 0--20 min: linear gradient from 80% to 20% B; 20--20.5 min: linear gradient from 20% to 80% B; 20.5--28 min: hold at 80% B. The mass spectrometer was operated in full scan, polarity-switching mode with the spray voltage set to 3.0 kV, the heated capillary held at 275°C, and the HESI probe held at 350°C. The sheath gas flow rate was set to 40 units, the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to one unit. The MS data acquisition was performed in a range of 70--1000 m/z, with the resolution set to 70,000, the AGC target at 1e6, and the maximum injection time at 20 msec.

After LC/MS analysis, metabolite identification was performed with XCalibur 2.2 software (Thermo Fisher Scientific, Waltham, MA) using a 5ppm mass accuracy and a 0.5 min. retention time window. For metabolite identification, external standard pools were used for assignment of metabolites to peaks at given *m/z* and retention time, and to determine the limit of detection for each metabolite, which ranged from 100 nM to 3 µM (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for the *m/z*, retention time and limit of detection for each metabolite analyzed).

After metabolite identification, quantification was performed by two separate methods for either quantification by stable isotope dilution or external standard calibration ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). For quantification by stable isotope dilution, where internal standards were available, we first compared the peak areas of the stable isotope labeled internal standards with the external standard pools diluted at known concentrations. This allowed for quantification of the concentration of labeled internal standards in the extraction mix. Subsequently, we compared the peak area of a given unlabeled metabolite in the TIF and plasma samples with the peak area of the now quantified internal standard to determine the concentration of that metabolite in the TIF or plasma sample. 70 metabolites were quantitated using this internal standard method (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for the metabolites quantitated with internal standards).

For metabolites without internal standards, quantification by external calibration was performed as described below ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). First, the peak area of each externally calibrated analyte was normalized to the peak area of a labeled amino acid internal standard that eluted at roughly the same retention time to account for differences in recovery between samples (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for the labeled amino acid paired to each metabolite analyzed without an internal standard). This normalization was performed in both biological samples and external standard pool dilutions. From the normalized peak areas of metabolites in the external standard pool dilutions, we generated a standard curve describing the relationship between metabolite concentration and normalized peak area. The standard curves were linear with fits typically at or above r^2^ = 0.95. Metabolites which did not meet these criteria were excluded from further analysis. These equations were then used to convert normalized peak areas of analytes in the TIF or plasma samples into analyte concentration in the samples. 74 metabolites were quantitated using this method. The relationship between metabolite concentration and normalized peak area is matrix dependent, and the external standards are prepared in water, which is a different matrix than either TIF or plasma. Therefore, we consider metabolite measurements using this external standard method semi-quantitative.

Measurement of relative intratumoral metabolite levels {#s4-6}
------------------------------------------------------

KP-/-C tumors were removed from animals as for TIF isolation. These tumors were then cut in half. One half was immediately cryogenically frozen using a BioSqueezer (BioSpec, Bartlesville, OK) cooled with liquid nitrogen. The other was subjected to TIF isolation as described above, and then similarly cryogenically frozen. Frozen tumor pieces were then then ground to a fine homogenous powder using a mortar and pestle cooled with liquid nitrogen. 15--32 mg of tumor powder was weighed into sample tubes, and metabolites were then extracted using 600 μL HPLC grade methanol (Sigma-Aldrich), 300 μL HPLC grade water (Sigma-Aldrich), and 400 μL chloroform (Sigma-Aldrich). The extraction mix included the following internal standards: 200 μM ^13^C and ^15^N labeled amino acids (Cambridge Isotope Laboratory, Andover, MA, MSK-A2-1.2), 200 μM ^13^C~4~ succinate (Cambridge Isotope Laboratory, Andover, MA, CLM-1571-PK) and 200 μM ^13^C~5~ hypoxanthine (Cambridge Isotope Laboratory, Andover, MA, CLM-8042). Samples were vortexed for 10 min at 4°C, then centrifuged at 21000 x g at 4°C for 10 min. 400 μL of the aqueous layer was removed and dried under nitrogen.

Dried tumor extracts were resuspended in 100 μL HPLC grade water and LC/MS was performed as described above for TIF and plasma samples. Relative quantitation of 112 detected metabolites (see [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"} for detected metabolites) was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific, Waltham, MA) using a five ppm mass tolerance and referencing an in-house library of chemical standards for identification of metabolites by exact mass and retention time. Hypoxanthine and xanthine peak areas were normalized to the ^13^C~5~ hypoxanthine internal standard and succinate was normalized to the ^13^C~4~ succinate peak area. All other metabolites were normalized to the ^13^C~5~ ^15^N~1~ leucine internal standard. All metabolites were normalized to the mass of tumor powder from which metabolites were extracted.

Statistical analysis of TIF and plasma metabolite levels {#s4-7}
--------------------------------------------------------

After determining the concentration of each metabolite in each plasma or TIF sample, all multivariate statistical analysis on the data was performed using Metaboanalyst 4.0 ([@bib15]). All metabolite concentrations were not normalized prior to analysis, but the data was auto-scaled (mean-centered and divided by the standard deviation of each variable) prior to analysis, as this method of scaling has been shown to perform well with metabolomics data ([@bib104]). After scaling the data, we performed principal component analysis and hierarchical clustering with Euclidean distance measurement and clustering by the Ward algorithm. Univariate analysis was performed comparing metabolite levels between groups where metabolite differences of interest were defined by a fold change greater than 1.5 and significance as a FDR-adjusted P-value less than 0.1 assuming unequal group variance. All other statistical analysis and graphical representation of data was performed as described in the Results using GraphPad Prism 7 (GraphPad Software, La Jolla, CA).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Ralph DeBerardinis as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Sean Morrison as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Christian Frezza (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Also, please note that while all reviewers saw value in Essential revisions 6 and 7, we appreciate that it may take more than 2 months to perform these experiments. We encourage you to include any such data you may have acquired or could acquire within 2 months to address these two points, but we would likely proceed with the paper even without these additional models, as long as the other points can be thoroughly addressed.

Summary:

Sullivan et al. applied quantitative metabolomics to measure metabolites in tumor interstitial fluid (TIF) from mice. They show that TIF metabolite content differs from plasma and is influenced by anatomic location, diet and, to a lesser extent, genetic factors. Altogether, the authors provide evidence that both tumor-intrinsic and tumor-extrinsic properties influence the metabolic makeup of the TIF, and they present a quantitative method to study this problem. The work is timely and the intriguing findings will present a valuable resource for the field of cancer metabolism.

Essential revisions:

1\) Although the authors were careful in isolating TIF, questions about artifacts will inevitably arise. Some additional discussion and (ideally) controls around these issues would be helpful. First, the authors carefully control against contamination of intracellular fluid in their prep, but it is unclear how or whether they know if the samples experience exchanges of metabolites into and out of TIF during the prep, thereby changing the apparent TIF concentrations. Some discussion around this issue would increase confidence in the findings. Second, can the authors clarify whether the procedure, which involves a period of ischemia, affects the tumor metabolome? For example, can the authors compare the metabolic signature of a freshly isolated tumor to one after the isolation of the TIF? Measurement of succinate and xanthine/hypoxanthine would help indicate the degree of ischemia experienced by the tissue.

2\) The authors state that metabolite levels in normal tissues more closely match circulating plasma concentrations. They should measure interstitial metabolites in normal pancreas and other relevant tissues and compare them to the changes the observe in TIF.

3\) Given the setup in the Introduction about high rates of glucose fermentation to lactate by tumors, it is relevant that lactate levels were not increased in the TIF in most experiments. I think readers would be interested in this finding, because it impacts how we think about glucose handling in these tumors. Could the authors show the lactate data in Figure 2?

4\) Most plasma vs TIF comparisons have a very different number of replicates per group. It may not have been possible to collect TIF from all tumors, but it would be helpful to illustrate the metabolic differences between matched plasma and TIF in the same mouse, perhaps as a supplementary figure.

5\) A related issue is the statistical tools used to compare TIF and plasma, because the unbalanced number of replicates may lead to erroneous p-values if not properly accounted for. It is not clear from the Materials and methods which statistical test was applied for these comparison (e.g. Figure 2D-J) and how the assumptions of the test were confirmed (e.g. normality of distribution, homogeneity of variance, etc.).

6\) The variation between subcutaneous and autochthonous tumor metabolites is intriguing. The manuscript and the field would benefit if orthotopic allografts were also included in this comparison.

7\) The authors speculate that cell intrinsic metabolic states and extrinsic factors such as circulation restriction by the stroma or high interstitial pressure exert major effects on TIF content. Some of these variables could be experimentally tested. For example, stroma can be depleted in KPC tumors, and interstitial pressure could be manipulated pharmacologically. These data, if available, would improve the paper and benefit the field.
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Author response

> Essential revisions:
>
> 1\) Although the authors were careful in isolating TIF, questions about artifacts will inevitably arise. Some additional discussion and (ideally) controls around these issues would be helpful. First, the authors carefully control against contamination of intracellular fluid in their prep, but it is unclear how or whether they know if the samples experience exchanges of metabolites into and out of TIF during the prep, thereby changing the apparent TIF concentrations. Some discussion around this issue would increase confidence in the findings. Second, can the authors clarify whether the procedure, which involves a period of ischemia, affects the tumor metabolome? For example, can the authors compare the metabolic signature of a freshly isolated tumor to one after the isolation of the TIF? Measurement of succinate and xanthine/hypoxanthine would help indicate the degree of ischemia experienced by the tissue.

We agree that while we have controlled for TIF contamination by intracellular material during TIF isolation, we had not addressed changes in TIF metabolite composition that could occur during the time that elapses during TIF harvest. It is difficult to perfectly control for how time required to harvest TIF affects TIF metabolite composition, because we do not currently have a method that allows for faster TIF isolation. We appreciate that a faster isolation method would allow us to make such a comparison and determine if any changes in TIF composition occur during the time elapsed when TIF is isolated by centrifugation. We are actively developing methods (e.g. TIF isolation using Guyton capsules PMID: 14190544) that would allow instantaneous TIF isolation, but developing these techniques requires extensive engineering and animal experiments that are not possible in a short time frame. Nevertheless, we agree this is an important point and at the reviewers' suggestion, we have added additional discussion on the potential limitations of TIF isolation by centrifugation in the Results section where we introduce the method.

To address the reviewers' second point, we have performed an additional experiment to determine the extent to which TIF isolation by centrifugation results in tumor ischemia and alterations in intratumoral metabolite levels, which may also influence what we measure in TIF. For this study, we isolated KP-/-C PDAC tumors, and cut the tumors in half. One half was immediately flash frozen, while TIF was isolated from the other half. The TIF-isolated half was then flash frozen. We then extracted metabolites from both tumor samples and compared relative metabolite levels (including the ischemia markers succinate, xanthine and hypoxanthine) between the matched fresh and TIF-isolated PDAC tumors. Fresh and TIF-isolate tumor samples did not cluster separately by principal component analysis of relative metabolite levels. We did observe small increases in xanthine and hypoxanthine levels in TIF-isolated tumor halves, but no increase in succinate levels. The increases in xanthine and hypoxanthine were much lower than observed previously in ischemic tissues (PMID: 25383517). These data suggest that the tumors likely experience a small degree of ischemia during the time needed to isolate TIF, but that this does not lead to significant changes in most intratumoral metabolite levels. While it is impossible to know how the TIF isolation employed affects the composition of the TIF itself, given the small degree of accumulation of ischemic markers in the tumors and that analysis of multiple metabolite levels between TIF-isolated and fresh tumors does not show stark differences, we suspect it is unlikely that ischemia experienced by the tumor during centrifugation substantially alters TIF composition. Consideration of these issues is also discussed in the revised manuscript, with the data included as Figure 1---figure supplement 1 and the raw relative abundances of metabolites included in Figure 1---source data 3.

> 2\) The authors state that metabolite levels in normal tissues more closely match circulating plasma concentrations. They should measure interstitial metabolites in normal pancreas and other relevant tissues and compare them to the changes the observe in TIF.

We agree with the reviewers that measuring the interstitial fluid of normal tissues and comparing this to tumor interstitial fluid would be very informative. We have repeatedly attempted to isolate interstitial fluid from normal murine organs using the same centrifugation method that we used to isolate TIF. Unfortunately, we were unable to isolate interstitial fluid from the normal organs. This could be due to a number of factors including the small size of mouse organs, and the lower interstitial volume and pressure of normal organs (PMID: 3555767). Thus, comparing TIF to normal tissue IF will require additional method development, including development and validation of another isolation method, that will take a substantial effort to complete. We nevertheless appreciate the point, and to address the reviewers' comment we have added additional discussion to the Results section that we were unable isolate murine tissue interstitial fluid, limiting the comparisons we can make at this time to TIF and the bulk circulation.

> 3\) Given the setup in the Introduction about high rates of glucose fermentation to lactate by tumors, it is relevant that lactate levels were not increased in the TIF in most experiments. I think readers would be interested in this finding, because it impacts how we think about glucose handling in these tumors. Could the authors show the lactate data in Figure 2?

We agree with the reviewers that this is an interesting observation, and we have included the lactate data in Figure 2.

> 4\) Most plasma vs TIF comparisons have a very different number of replicates per group. It may not have been possible to collect TIF from all tumors, but it would be helpful to illustrate the metabolic differences between matched plasma and TIF in the same mouse, perhaps as a supplementary figure.

We agree that analysis of matched plasma and TIF samples is informative for interpreting the data. We have now included the same analysis as performed in Figure 2 using only matched PDAC TIF and plasma samples. The results are shown in Figure 2---figure supplement 2. We note that the same differences between plasma and TIF we observed between all PDAC TIF and plasma samples are largely mirrored in analysis of only the paired samples.

> 5\) A related issue is the statistical tools used to compare TIF and plasma, because the unbalanced number of replicates may lead to erroneous p-values if not properly accounted for. It is not clear from the Materials and methods which statistical test was applied for these comparison (e.g. Figure 2D-J) and how the assumptions of the test were confirmed (e.g. normality of distribution, homogeneity of variance, etc.).

We thank the reviewers for identifying this concern and apologize that it was not sufficiently clear which statistical analyses we performed for comparisons of individual metabolite levels. The unpaired two-tailed Welch's t-test we were using in Figure 2, Figure 3 and Figure 6 accounts for unequal variance and sample number between groups, but does rely upon normality of distribution, which we did not test. To address this issue, we used the Shapiro-Wilk test to test for normality of distribution for all individual metabolite comparisons shown throughout. The distributions were largely normal, and where this was the case we used the same unpaired two-tailed Welch's t-test now knowing that the condition of normality of distribution was met. Where the distribution was not normal, we used Wilcoxon matched-pairs signed rank test to test for significance, as this test does not require normality of distribution. We have updated the figure legends to indicate exactly which tests were utilized for each metabolite comparisons presented. Importantly, applying the correct statistical tests did not change which differences were statistically insignificant and did not alter our interpretation of the data.

> 6\) The variation between subcutaneous and autochthonous tumor metabolites is intriguing. The manuscript and the field would benefit if orthotopic allografts were also included in this comparison.

We agree that comparison of TIF from different PDAC models, including orthotopic allografts, would be useful in helping researchers select appropriate mouse models for their studies. We also agree that it would strengthen the conclusion that we have drawn from the data that anatomical location could impact the tumor nutrient environment. Unfortunately, generating and isolating TIF from PDAC orthotopic allograft tumors was not possible in the time allowed for revision, but are working on addressing this question to better understand how anatomical location influences TIF composition, and to determine whether allograft models recapitulate the TIF microenvironment of autochthonous tumors. We have also included discussion of this point in the Results section of the revised manuscript.

> 7\) The authors speculate that cell intrinsic metabolic states and extrinsic factors such as circulation restriction by the stroma or high interstitial pressure exert major effects on TIF content. Some of these variables could be experimentally tested. For example, stroma can be depleted in KPC tumors, and interstitial pressure could be manipulated pharmacologically. These data, if available, would improve the paper and benefit the field.

We agree with the reviewers that some cancer cell intrinsic and extrinsic factors that we speculate alter TIF composition could be experimentally tested. We anticipate studies that manipulate tumor cells, stromal cells and vasculature will shed more light on what factors influence the metabolic composition of tumors. As noted in the decision letter, these experiments are complicated and require commitment of time and effort that was not possible within the timeframe of the revision. However, we do think this is a critical point that warrants future studies, and have thus included a new section on this point in the Discussion of the revised manuscript.
